Affordable Access

Effect of Imiquimod and derivatives compounds EAPB0203 and EAPB0503 on Leukemia/lymphoma models

Authors
  • Nabbouh, Ali
Publication Date
Dec 16, 2016
Source
Kaleidoscope Open Archive
Keywords
Language
English
License
Unknown
External links

Abstract

Acute myeloid leukemia (AML) is a heterogeneous clonal disorder characterized by immature myeloid cell proliferation and bone marrow failure. Although the remarkable improvements in the field and regarding new drug targets and better understanding of the biology, the clinical treatment of AML remains unchanged and depending on karyotype of patients. For the last thirty years with the majority of patients, in the end, relapsing and dying of the disease, there is no standard regimen that improves prognosis and treat AML yet.Imidazoquinoxalines are imiquimod derivatives with indirect immunomodulatory effect and direct antitumor activity on melanoma and T-cell lymphoma, attributed to growth inhibition and induction of apoptosis through caspase-dependent pathway. We examined the effects of imidazoquinoxaline derivatives, EAPB0203 and EAPB0503, on human AML cells. We found that EAPB0503 inhibit cell growth of AML cell line that harbors the NPM-1 mutation in a time- and dose-dependent way. Compared to the previously synthesized EAPB0203, EAPB0503 has a more pronounced inhibitory activity on OCI-AML3 cells and cells derived from AML patients as well. We demonstrated that the EAPB0503 induces proteasome-mediated degradation of mutant NPM-1, and restoration of the nucleolar localization of the NPM-1wt leading to an inhibition of the proliferation of OCI-AML3 cells.EAPB0503 induced massive apoptosis as demonstrated with the cell cycle analysis by the accumulation of treated cells in the preG0 region. Apoptosis has been confirmed by Annexin V positivity, PARP cleavage, and dissipation of mitochondrial membrane potential in treated OCI-AML3 cells.Furthermore, EAPB0503 increased the expression and phosphorylation levels of p53.These results in growth inhibition and apoptosis, selectively in AML cells that harbor the NPM-1 mutation reinforce the idea targeting NPM-1m oncoprotein to eradicate leukemic cells and warrant a broader preclinical then clinical evaluation of this promising drug.In conclusion, our studies highlight the use of EAPB0503 as a promising anti-tumor activity to be investigated preclinically in AML targeted therapy.

Report this publication

Statistics

Seen <100 times